Natixis Advisors, L.P. Ionis Pharmaceuticals Inc Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Natixis Advisors, L.P. holds 21,080 shares of IONS stock, worth $732,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,080
Previous 23,404
9.93%
Holding current value
$732,530
Previous $1.12 Million
24.3%
% of portfolio
0.0%
Previous 0.0%
Shares
29 transactions
Others Institutions Holding IONS
# of Institutions
403Shares Held
136MCall Options Held
862KPut Options Held
582K-
Vanguard Group Inc Valley Forge, PA15.1MShares$523 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$492 Million0.34% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$359 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.74MShares$304 Million0.06% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$274 Million5.32% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $4.93B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...